With a focus on improving patient outcomes through evidence-based healing solutions and services, Sanara MedTech Inc. markets and distributes wound and skin care products and is seeking to offer wound care and dermatology virtual consultation services via telemedicine to physicians, hospitals, clinics, and all post-acute care settings. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™ Hydrolyzed Collagen Powder and Gel. The company is constantly seeking long-term strategic partnerships with a focus on products and technologies that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry.
Company profile
Ticker
SMTI
Exchange
Website
CEO
J. Michael Carmena
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • Edwards Lifesciences • Invacare • MSA Safety • Align Technology • Surgalign ...
Former names
INAV TRAVEL CORPORATION, MB SOFTWARE CORP, WOUND MANAGEMENT TECHNOLOGIES, INC.
SEC CIK
Corporate docs
Subsidiaries
Cellerate, LLC • Wound Care Innovations, LLC • Sanara Biologics, LLC • Rochal Technologies, LLC • WounDerm, LLC • United Wound and Skin Solutions, LLC • Precision Healing, LLC • Scendia Biologics, LLC ...
IRS number
592220004
SMTI stock data
Latest filings (excl ownership)
8-K
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results
20 Mar 23
10-K
2022 FY
Annual report
20 Mar 23
8-K
Entry into a Material Definitive Agreement
24 Feb 23
424B5
Prospectus supplement for primary offering
24 Feb 23
8-K
Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022
22 Feb 23
8-K
Regulation FD Disclosure
16 Dec 22
8-K
Departure of Directors or Certain Officers
6 Dec 22
8-K
Regulation FD Disclosure
30 Nov 22
8-K/A
Results of Operations and Financial Condition
15 Nov 22
8-K
Sanara MedTech Inc. Announces Third Quarter 2022 Results
14 Nov 22
Transcripts
SMTI
Earnings call transcript
2022 Q4
21 Mar 23
SMTI
Earnings call transcript
2022 Q3
15 Nov 22
SMTI
Earnings call transcript
2022 Q2
16 Aug 22
SMTI
Earnings call transcript
2022 Q1
17 May 22
SMTI
Earnings call transcript
2021 Q4
31 Mar 22
SMTI
Earnings call transcript
2021 Q3
15 Nov 21
SMTI
Earnings call transcript
2021 Q2
17 Aug 21
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 8.96 mm | 8.96 mm | 8.96 mm | 8.96 mm | 8.96 mm | 8.96 mm |
| Cash burn (monthly) | 442.13 k | 807.82 k | 1.39 mm | 1.12 mm | 215.01 k | 462.91 k |
| Cash used (since last report) | 1.29 mm | 2.36 mm | 4.06 mm | 3.29 mm | 629.28 k | 1.35 mm |
| Cash remaining | 7.66 mm | 6.59 mm | 4.90 mm | 5.67 mm | 8.33 mm | 7.60 mm |
| Runway (months of cash) | 17.3 | 8.2 | 3.5 | 5.0 | 38.7 | 16.4 |
Institutional ownership, Q4 2022
1.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 30 |
| Opened positions | 9 |
| Closed positions | 5 |
| Increased positions | 9 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 13.57 bn |
| Total shares | 356.96 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 96.06 k | $4.37 bn |
| EAM Investors | 54.76 k | $2.49 bn |
| Geode Capital Management | 28.11 k | $1.28 mm |
| North Run Capital L P | 24.00 k | $1.09 bn |
| Susquehanna International | 15.23 k | $692.83 mm |
| AMP Ameriprise Financial | 13.85 k | $629.00 mm |
| Citadel Advisors | 12.57 k | $571.94 mm |
| Salem Investment Counselors | 11.21 k | $510.06 mm |
| Bamco | 10.71 k | $487.08 mm |
| STT State Street | 9.81 k | $446.49 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Mar 23 | Rebecca E McMahon | Common Stock | Payment of exercise | Dispose F | No | No | 41.5 | 201 | 8.34 k | 9,595 |
| 17 Mar 23 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 41.5 | 532 | 22.08 k | 22,025 |
| 17 Mar 23 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 43.3 | 253 | 10.95 k | 22,557 |
| 17 Mar 23 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 40.5 | 658 | 26.65 k | 22,810 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 41.5 | 717 | 29.76 k | 40,243 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 43.3 | 325 | 14.07 k | 40,960 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 40.5 | 812 | 32.89 k | 41,285 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 40.5 | 1,101 | 44.59 k | 42,097 |
| 2 Mar 23 | Fleming Zachary B. | Common Stock | Grant | Acquire A | No | No | 0 | 1,736 | 0.00 | 43,198 |
| 2 Mar 23 | Fleming Zachary B. | Common Stock | Grant | Acquire A | No | No | 0 | 6,988 | 0.00 | 41,462 |